Fortress biotech announces first patient dosed in phase 2 clinical trial of triplex vaccination in stem cell donors to reduce cmv events in recipients of hsct

Study is the first randomized, controlled trial examining a vaccine's effectiveness in controlling cmv in recipients of hsct from vaccinated donors

STEM Ratings Summary

STEM Quant Ranking